Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189708 | 0.83 | ALDH1A1 (0.57) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL611462 | 0.80 | MEN1 (0.54) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL30089319 | 0.80 | MEN1 (0.48) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL23881561 | 0.80 | MEN1 (0.48) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL2704894 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL30402632 | 0.79 | AGER (0.52) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL2704116 | 0.79 | ALDH1A1 (0.59) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL15608370 | 0.79 | MAPK14 (0.50) | ALDH1A1CES2CES1RECQLMAPK14 | |
| SCHEMBL250099 | 0.79 | CES2 (0.71) | ALDH1A1ALOX15MAPTCES2CES1 | |
| SCHEMBL30293901 | 0.79 | CES2 (0.71) | ALDH1A1ALOX15MAPTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
| US-3941803-A | 2-(Imidazol-1-yl)benzophenones | THE UPJOHN COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | ALDH1A1 1169/4885ALOX15 3842/4885MAPT 4445/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | ALDH1A1 1169/4885ALOX15 3842/4885MAPT 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.